…
IR-Med Inc., a medical device company, engages in the development of non-invasive devices for various medical indications. The company's development products pipeline consists of PressureSafe, a handheld skin-agnostic optical monitoring device that supports early detection of pressure injuries to the skin and underlying tissue primarily caused by prolonged pressure associated with bed confinement; DiaSafe, a handheld optical monitoring device, which supports early detection of diabetic foot ulcers in lower limb skin and underlying tissue caused by prolonged pressure on the sole of diabetic patients; and Nobiotics, an otoscope to support physicians with an immediate indication as to whether mid-ear, a common malady in children. IR-Med Inc. is headquartered in Rosh Pinna, Israel.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
International Display Advertising Inc (OTCQB: IRME) is an OTCQB-listed company; public disclosures are limited and the firm's core operations, revenue sources and strategy are not clearly documented. The company's long-term prospects may depend on establishing a verifiable business model, producing audited financial statements and executing growth initiatives that clarify its market position.
Material risks include low trading liquidity and wide spreads typical of microcap OTC listings, lack of audited financials and operating history, execution and financing risk that could lead to severe dilution, and broader regulatory and compliance exposure.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Income before tax | -1.90M | -4.91M | -4.73M | -3.72M | -0.75M |
| Net income | -1.90M | -4.91M | -4.73M | -3.72M | -0.75M |
| Selling general administrative | 1.15M | 2.71M | 2.74M | 2.18M | 0.32M |
| Reconciled depreciation | 0.02M | 0.02M | 0.01M | 0.01M | 0.00M |
| Ebit | - | - | -4.76M | -3.67M | -0.73M |
| Ebitda | - | - | -4.72M | -3.71M | -0.74M |
| Operating income | -1.94M | -4.91M | -4.76M | -3.67M | -0.73M |
| Interest expense | - | - | 0.01M | 0.01M | 0.01M |
| Interest income | - | 0.02M | - | - | - |
| Net interest income | -0.00M | 0.02M | -0.01M | -0.01M | -0.01M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 1.94M | 4.91M | 4.76M | 3.67M | 0.73M |
| Total other income expense net | 0.05M | -0.02M | 0.04M | -0.04M | -0.01M |
| Net income from continuing ops | -1.90M | -4.91M | -4.73M | -3.72M | -0.75M |
| Net income applicable to common shares | - | - | -4.73M | -3.72M | -0.75M |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Total assets | 0.25M | 1.00M | 3.29M | 2.94M | 2.09M |
| Other current assets | - | - | - | - | 0.19M |
| Total liab | 0.55M | 0.63M | 0.70M | 0.57M | 0.69M |
| Total stockholder equity | -0.29M | 0.36M | 2.59M | 2.37M | 1.40M |
| Other current liab | - | - | 0.11M | 0.03M | 0.02M |
| Common stock | - | - | 0.07M | 0.06M | 0.05M |
| Capital stock | 0.07M | 0.07M | 0.07M | 0.06M | 0.05M |
| Retained earnings | -16.74M | -14.84M | -9.93M | -5.20M | -1.48M |
| Other assets | - | - | 0.01M | 0.03M | - |
| Cash | 0.13M | 0.77M | 3.00M | 2.81M | 1.87M |
| Total current liabilities | 0.55M | 0.47M | 0.66M | 0.40M | 0.52M |
| Net debt | 0.03M | - | - | - | - |
| Short long term debt | 0.16M | - | 0.16M | - | - |
| Other stockholder equity | - | - | - | - | 0.02M |
| Property plant equipment | - | - | 0.23M | 0.03M | 0.01M |
| Total current assets | 0.20M | 0.85M | 3.06M | 2.88M | 2.08M |
| Net tangible assets | - | - | 2.59M | 2.37M | 1.40M |
| Net receivables | - | - | 0.04M | 0.07M | 0.03M |
| Long term debt | - | 0.16M | - | 0.18M | 0.17M |
| Accounts payable | 0.06M | 0.06M | 0.07M | 0.06M | 0.03M |
| Non currrent assets other | 0.01M | 0.01M | 0.01M | - | - |
| Non current assets total | 0.05M | 0.15M | 0.24M | 0.06M | 0.01M |
| Capital lease obligations | 0.00M | 0.04M | 0.11M | - | - |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Investments | 0.00M | 0.00M | -0.06M | -0.06M | 0.00M |
| Change to liabilities | - | - | 0.04M | -0.08M | 0.32M |
| Total cashflows from investing activities | - | - | -0.06M | -0.06M | -0.06M |
| Net borrowings | -0.01M | 0.00M | - | - | - |
| Total cash from financing activities | 0.75M | 1.00M | 3.62M | 3.49M | 2.04M |
| Change to operating activities | - | - | - | - | 0.02M |
| Net income | -1.90M | -4.91M | -4.73M | -3.72M | -0.75M |
| Change in cash | -0.64M | -2.23M | 0.19M | 0.95M | 1.63M |
| Begin period cash flow | 0.77M | 3.00M | 2.81M | 1.87M | 0.23M |
| End period cash flow | 0.13M | 0.77M | 3.00M | 2.81M | 1.87M |
| Total cash from operating activities | -1.39M | -3.23M | -3.38M | -2.48M | -0.40M |
| Issuance of capital stock | 0.76M | 1.00M | 3.62M | 3.49M | 2.04M |
| Depreciation | 0.02M | 0.02M | 0.01M | 0.01M | 0.00M |
| Other cashflows from investing activities | - | - | -0.01M | -0.03M | -0.03M |
| Change to account receivables | 0.01M | -0.03M | 0.01M | -0.04M | -0.02M |
| Change to netincome | - | - | 1.30M | 1.35M | 0.04M |
| Capital expenditures | 0.00M | 0.00M | 0.05M | 0.03M | 0.03M |
| Change in working capital | 0.01M | -0.02M | 0.05M | -0.12M | 0.30M |
| Stock based compensation | 0.48M | 1.68M | 1.33M | 1.34M | 0.00M |
| Other non cash items | 0.00M | -0.00M | -0.03M | 0.01M | 0.02M |
| Free cash flow | -1.39M | -3.23M | -3.42M | -2.51M | -0.40M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| IRME International Display Advertising Inc |
- -% |
0.00 | - | - | - | 66.26 | -6.76 |
| ABT Abbott Laboratories |
-0.71 0.65% |
108.58 | 25.97 | 17.24 | 3.57 | 3.20 | 16.75 |
| MDT Medtronic PLC |
0.28 0.28% |
101.89 | 26.60 | 15.87 | 3.35 | 2.08 | 14.12 |
| SYK Stryker Corporation |
-2.16 0.68% |
316.63 | 29.23 | 16.86 | 4.18 | 4.51 | 17.16 |
| SEMHF Siemens Healthineers AG |
- -% |
47.31 | 39.57 | 21.32 | 3.01 | 3.29 | 16.92 |
IR-Med Inc., a medical device company, engages in the development of non-invasive devices for various medical indications. The company's development products pipeline consists of PressureSafe, a handheld skin-agnostic optical monitoring device that supports early detection of pressure injuries to the skin and underlying tissue primarily caused by prolonged pressure associated with bed confinement; DiaSafe, a handheld optical monitoring device, which supports early detection of diabetic foot ulcers in lower limb skin and underlying tissue caused by prolonged pressure on the sole of diabetic patients; and Nobiotics, an otoscope to support physicians with an immediate indication as to whether mid-ear, a common malady in children. IR-Med Inc. is headquartered in Rosh Pinna, Israel.
| Name | Title | Year Born |
|---|---|---|
| Mr. Oded Bashan | Co-Founder & Chairman | 1947 |
| Mr. Aharon Klein | Co-Founder, CTO & Director | 1965 |
| Mr. Aharon Binur | Chief Devel. Officer | 1964 |
| Mr. Moshe Gerber | Chief Exec. Officer | 1961 |
| Mr. Yaniv Cohen | Co-Founder, R&D Researcher and Director | 1980 |
| Mr. Sharon Levkoviz | Chief Financial Officer | 1974 |
| Mr. Yoram Drucker | VP of Bus. Devel. & Director | 1965 |
| Mr. Avi Vachnis | Head of Software & AI | NA |
| Mr. Aharon Klein | Co-Founder, CTO & Director | 1962 |
| Dr. Yaniv Cohen M.Sc., Ph.D. | Co-Founder, Chief Scientific Officer & Director | 1981 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.